Robert Lewis, MD
Neurology · Hurricane, WVNPI 1811097348
Payments from drug & device makers
Across 600 payments — averaging $120.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viz.ai, Inc.$42K
- AbbVie$27K
- Pfizer$625
- UCB, Inc.$491
- Biohaven Pharmaceutical Holding Company Ltd.$346
- Amgen$281
- plus $2K from 25 others
What the payments were for
- Consulting fees$42,39158%
- Speaking & faculty fees$22,11330%
- Food & beverage$7,81511%
- Education$2590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viz.ai, Inc. | 1 | $42,391 |
| AbbVie(2 entities) | 360 | $26,812 |
| Pfizer | 100 | $625 |
| UCB, Inc. | 25 | $491 |
| Biohaven Pharmaceutical Holding Company Ltd. | 28 | $346 |
| Amgen | 29 | $281 |
| Jazz Pharmaceuticals Inc. | 8 | $275 |
| AstraZeneca | 4 | $225 |
| Biogen | 3 | $132 |
| Alnylam Pharmaceuticals Inc. | 1 | $125 |
| ANI Pharmaceuticals, Inc. | 1 | $124 |
| Medtronic(2 entities) | 5 | $95 |
| EMD Serono, Inc. | 2 | $80 |
| Vanda Pharmaceuticals Inc. | 3 | $78 |
| Novartis | 5 | $73 |
| Akcea Therapeutics, Inc. | 4 | $70 |
| Tanabe Pharma America, Inc. | 4 | $63 |
| Neurocrine Biosciences, Inc. | 2 | $38 |
| Supernus Pharmaceuticals, Inc. | 2 | $33 |
| Otsuka America Pharmaceutical, Inc. | 2 | $31 |
| Biohaven Pharmaceuticals, Inc. | 1 | $23 |
| Greenwich Biosciences, Inc. | 1 | $22 |
| Argenx US, Inc. | 1 | $21 |
| Banner Life Sciences, LLC | 1 | $19 |
| Boston Scientific | 1 | $17 |
| TG Therapeutics, Inc. | 1 | $17 |
| Neurelis, Inc. | 1 | $16 |
| Kyowa Kirin, Inc. | 1 | $14 |
| Livanova USA, Inc. | 1 | $14 |
| Acorda Therapeutics, Inc | 1 | $13 |
| Impel Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Viz.AI LVO$42,391
- UBRELVY$22,411
- QULIPTA$3,250
- ULTOMIRIS$200
- ONPATTRO$125
- Nayzilam$125
- PURIFIED CORTROPHIN GEL$124
How this compares
$72,578 in reported general payments places this provider in the 85th percentile of 93 neurology providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 11 | $210,205 |
| RebifInterferon Beta-1a/Albumin | 17 | $177,866 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 12 | $154,297 |
| XywavSodium,calcium,mag,pot Oxybate | 11 | $115,323 |
| EpidiolexCannabidiol (Cbd) | 15 | $76,355 |
| Nurtec OdtRimegepant Sulfate | 45 | $63,699 |
| BriviactBrivaracetam | 26 | $42,612 |
| Aimovig AutoinjectorErenumab-Aooe | 47 | $37,467 |
| BotoxOnabotulinumtoxina | 35 | $34,855 |
| UbrelvyUbrogepant | 24 | $28,552 |
| Ajovy SyringeFremanezumab-Vfrm | 17 | $17,389 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 17 | $15,668 |
| Emgality PenGalcanezumab-Gnlm | 13 | $12,807 |
| NayzilamMidazolam | 20 | $12,268 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 159 | $5,022 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| EMD Serono, Inc.Rebif | $80 | $177,86617 claims |
| PfizerNurtec Odt | $625 | $63,69945 claims |
| AbbVieBotox, Ubrelvy | $26,812 | $63,40759 claims |
| UCB, Inc.Briviact, Nayzilam | $491 | $54,88146 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 93 neurology providers in West Virginia.
Other neurology in Hurricane
- Barry VaughtCrab Orchard$3M
- Melanie WardMorgantown$1.4M
- Paul FergusonHuntington$754K
- Umer NajibMorgantown$477K
- Cheryl SmithMorgantown$394K
- Lauren SeebergerCharleston$288K
- Ann MurrayMorgantown$266K
- Shumaila SultanMorgantown$134K
- Eric SeachristMorgantown$95K
- Muhammed Nasher-AlneamCharleston$73K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.